Carmell Therapeutics Stock Today
| CTCX Stock | 0.25 0.01 4.17% |
Performance0 of 100
| Odds Of DistressOver 65
|
Carmell Therapeutics is trading at 0.25 as of the 25th of November 2024; that is 4.17% increase since the beginning of the trading day. The stock's open price was 0.24. Carmell Therapeutics has more than 65 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Carmell Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of July 2023 | Category Consumer Defensive | Classification Health Care |
Carmell Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 20.91 M outstanding shares of which 505.09 K shares are currently shorted by private and institutional investors with about 0.04 trading days to cover. More on Carmell Therapeutics
Moving together with Carmell Stock
Moving against Carmell Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Carmell Stock Highlights
| Executive Chairman | Rajiv Shukla | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Consumer Defensive, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
| Carmell Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Carmell Therapeutics' financial leverage. It provides some insight into what part of Carmell Therapeutics' total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||||||||||||
Carmell Therapeutics (CTCX) is traded on NASDAQ Exchange in USA. It is located in 2403 Sidney Street, Pittsburgh, PA, United States, 15203 and employs 9 people. Carmell Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.13 M. Carmell Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 20.91 M outstanding shares of which 505.09 K shares are currently shorted by private and institutional investors with about 0.04 trading days to cover.
Carmell Therapeutics generates negative cash flow from operations
Check Carmell Therapeutics Probability Of Bankruptcy
Ownership AllocationCarmell Therapeutics holds a total of 20.91 Million outstanding shares. Carmell Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Carmell Ownership Details
Carmell Therapeutics Historical Income Statement
Carmell Stock Against Markets
Carmell Therapeutics Corporate Executives
Elected by the shareholders, the Carmell Therapeutics' board of directors comprises two types of representatives: Carmell Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Carmell. The board's role is to monitor Carmell Therapeutics' management team and ensure that shareholders' interests are well served. Carmell Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Carmell Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.